Dakota Wealth Management Increases Stake in IDEXX Laboratories, Inc. $IDXX

Dakota Wealth Management grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 90.4% during the 3rd quarter, Holdings Channel reports. The fund owned 4,243 shares of the company’s stock after buying an additional 2,015 shares during the period. Dakota Wealth Management’s holdings in IDEXX Laboratories were worth $2,711,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Blalock Williams LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $590,000. New York State Common Retirement Fund lifted its holdings in IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after purchasing an additional 3,820 shares in the last quarter. Arkadios Wealth Advisors bought a new position in shares of IDEXX Laboratories in the second quarter worth approximately $405,000. Mediolanum International Funds Ltd increased its stake in shares of IDEXX Laboratories by 14.5% in the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after purchasing an additional 4,909 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after purchasing an additional 187,967 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, BTIG Research cut their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $649.35 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The stock has a 50 day moving average of $675.31 and a 200 day moving average of $669.07. The firm has a market cap of $51.70 billion, a PE ratio of 49.68, a PEG ratio of 3.79 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the company earned $2.53 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This trade represents a 53.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael G. Erickson sold 5,371 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 18,180 shares of company stock worth $11,626,996 over the last 90 days. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.